Ryan Haumschild

Featured in: Favicon

ajmc.com

pharmacytimes.com Favicon

onclive.com Favicon

neurologylive.com Favicon

jhoponline.com Favicon

valuebasedcancer.com

Articles

Bispecifics in Combination Therapies for B-Cell Lymphomas

Jan 17, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL? Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others?
Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

Jan 17, 2025 | ajmc.com | Ryan Haumschild

OpinionVideoJanuary 17, 2025Author(s):,Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.
Deciding When to Treat Patients With Alopecia Areata

Jan 15, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:McMichael: In which patients do you treat AA vs use observation? Is there a scoring system that you use? Source link
Choosing an Initial Therapy for Alopecia Areata

Jan 15, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:Ungar: Which key factors influence your choice of initial therapy for patients with AA? Which drug classes do payers initially require in patients recently diagnosed with AA? Which therapies have the highest success rate? Which therapies have the lowest success rate? Source link
Epidemiology Associated wWith Alopecia Areata

Jan 13, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice? a. Is there a population in which you have seen most commonly have AA occurs more frequently in based on your clinical experience? Source link
Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Jan 10, 2025 | ajmc.com | Ryan Haumschild

Opinion Video January 10, 2025 Author(s): , Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address...
Diagnosis of Alopecia Areata

Jan 8, 2025 | businessandamerica.com | Ryan Haumschild

Your email address will not be published. Save my name, email, and website in this browser for the next time I comment.
Multimodal Care for Patients With Alopecia Areata

Jan 8, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:McMichael: Which healthcare specialties are involved in managing treating patients with AA, and how can multidisciplinary care be optimized? Friedland: How do you alleviate any financial barriers related to care that the patient may experience? Source link
Safety Profiles of Neurokinin-Targeted Therapies for VMS

Nov 19, 2024 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:(PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant? (FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments? Source link
Oral vs. IV HMAs: Considerations and Patient Guidance

Sep 24, 2024 | ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca

OpinionVideoSeptember 24, 2024Author(s):Medical experts discuss considerations and patient guidance for oral and IV HMAs.Video content above is prompted by the following:What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient preferences?